Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
index medicus (19) 19
pharmacokinetics (18) 18
female (17) 17
rilpivirine (17) 17
male (16) 16
pharmacology & pharmacy (16) 16
adult (15) 15
safety (13) 13
middle aged (12) 12
pyrimidines - adverse effects (12) 12
human immunodeficiency virus--hiv (11) 11
nitriles - adverse effects (11) 11
pyrimidines - administration & dosage (11) 11
antiretroviral drugs (10) 10
nitriles - administration & dosage (10) 10
efavirenz (9) 9
infectious diseases (9) 9
young adult (9) 9
adolescent (8) 8
anti-hiv agents - administration & dosage (8) 8
drug interactions (8) 8
efficacy (8) 8
hiv (8) 8
hiv infections - drug therapy (8) 8
pyrimidines - pharmacokinetics (8) 8
treatment outcome (8) 8
anti-hiv agents - adverse effects (7) 7
emtricitabine (7) 7
etravirine (7) 7
immunology (7) 7
nitriles - pharmacokinetics (7) 7
pharmacology (7) 7
hiv-1 (6) 6
animals (5) 5
anti-hiv agents - pharmacology (5) 5
antiretroviral therapy (5) 5
benzoxazines - administration & dosage (5) 5
clinical trials (5) 5
hiv reverse transcriptase - antagonists & inhibitors (5) 5
hiv-1 - drug effects (5) 5
internal medicine (5) 5
phase-3 (5) 5
research (5) 5
reverse transcriptase inhibitors - pharmacokinetics (5) 5
tenofovir (5) 5
tmc278 (5) 5
aged (4) 4
aids/hiv (4) 4
anti-hiv agents - therapeutic use (4) 4
antiviral agents (4) 4
atherosclerosis (4) 4
benzoxazines - adverse effects (4) 4
darunavir (4) 4
dosage and administration (4) 4
double-blind (4) 4
drug administration schedule (4) 4
hiv infections - virology (4) 4
mice (4) 4
mice, inbred c57bl (4) 4
nitriles - pharmacology (4) 4
non-nucleoside reverse transcriptase inhibitor (4) 4
pyridazines - pharmacokinetics (4) 4
pyrimidines - pharmacology (4) 4
reverse transcriptase inhibitors - administration & dosage (4) 4
therapy (4) 4
trial (4) 4
virology (4) 4
abridged index medicus (3) 3
adults (3) 3
anti-hiv agents - pharmacokinetics (3) 3
area under curve (3) 3
bioavailability (3) 3
combination (3) 3
cross-over studies (3) 3
dose-response relationship, drug (3) 3
double-blind method (3) 3
drug dosages (3) 3
drug therapy (3) 3
drug therapy, combination (3) 3
healthy volunteers (3) 3
injections, intramuscular (3) 3
medicine & public health (3) 3
medicine, general & internal (3) 3
metabolism (3) 3
mutation (3) 3
nitriles - therapeutic use (3) 3
nucleotides (3) 3
pregnancy (3) 3
pyrimidines - blood (3) 3
pyrimidines - therapeutic use (3) 3
reverse transcriptase inhibitors - adverse effects (3) 3
reverse transcriptase inhibitors - pharmacology (3) 3
thrive (3) 3
usage (3) 3
abstract supplement (2) 2
acquired immune deficiency syndrome--aids (2) 2
acquired immunodeficiency syndrome - drug therapy (2) 2
acquired immunodeficiency syndrome - ethnology (2) 2
acquired immunodeficiency syndrome - virology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof and Cahn, Pedro, MD and Grinsztejn, Beatriz, MD and Lazzarin, Adriano, Prof and Mills, Anthony, MD and Saag, Michael, Prof and Supparatpinyo, Khuanchai, Prof and Walmsley, Sharon, Prof and Crauwels, Herta, PhD and Rimsky, Laurence T, PhD and Vanveggel, Simon, MSc and Boven, Katia, MD and ECHO Study Grp and ECHO study group
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
by Cohen, Calvin J, Dr and Andrade-Villanueva, Jaime, Prof and Clotet, Bonaventura, MD and Fourie, Jan, MD and Johnson, Margaret A, Prof and Ruxrungtham, Kiat, Prof and Wu, Hao, MD and Zorrilla, Carmen, MD and Crauwels, Herta, PhD and Rimsky, Laurence T, PhD and Vanveggel, Simon, MSc and Boven, Katia, MD and THRIVE Study Grp and THRIVE study group
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
by Margolis, David A and Gonzalez-Garcia, Juan and Stellbrink, Hans-Jürgen and Eron, Joseph J and Yazdanpanah, Yazdan and Podzamczer, Daniel and Lutz, Thomas and Angel, Jonathan B and Richmond, Gary J and Clotet, Bonaventura and Gutierrez, Felix and Sloan, Louis and Clair, Marty St and Murray, Miranda and Ford, Susan L and Mrus, Joseph and Patel, Parul and Crauwels, Herta and Griffith, Sandy K and Sutton, Kenneth C and Dorey, David and Smith, Kimberly Y and Williams, Peter E and Spreen, William R
The Lancet, ISSN 0140-6736, 09/2017, Volume 390, Issue 10101, pp. 1499 - 1510
Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting... 
MEDICINE, GENERAL & INTERNAL | GSK1265744 | PHARMACOKINETICS | SAFETY | PHARMACOLOGY | ANTIRETROVIRAL THERAPY | FORMULATION | SIMPLIFICATION | BOOSTED PROTEASE INHIBITOR | HIV (Viruses) | Adults | Analysis | Health care | Antiretroviral drugs | Acquired immune deficiency syndrome--AIDS | Research & development--R&D | Human immunodeficiency virus--HIV | Clinical trials | Mutation | Disease management | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
by Susan L. Ford and Elizabeth Gould and Shuguang Chen and David Margolis and William Spreen and Herta Crauwels and Stephen Piscitelli
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2013, Volume 57, Issue 11, pp. 5472 - 5477
OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
RALTEGRAVIR | EFFICACY | SAFETY | DOUBLE-BLIND | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | NAIVE ADULTS | S/GSK1349572 | ETRAVIRINE | Reverse Transcriptase Inhibitors - blood | Area Under Curve | Pyrimidines - blood | Rilpivirine | Humans | Middle Aged | Male | Healthy Volunteers | Nitriles - pharmacokinetics | Pyridones - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Adult | Female | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Drug Administration Schedule | Pyridones - pharmacokinetics | Administration, Oral | HIV Integrase Inhibitors - pharmacokinetics | Cross-Over Studies | Heterocyclic Compounds, 3-Ring - blood | Nitriles - blood | Pyrimidines - pharmacokinetics | HIV Integrase Inhibitors - blood | Drug Combinations | Antiviral Agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine
by Green, Bruce and Crauwels, Herta and Kakuda, Thomas N and Vanveggel, Simon and Brochot, Anne
Clinical Pharmacokinetics, ISSN 0312-5963, 05/2017, Volume 56, Issue 5, pp. 525 - 536
Background Etravirine is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretrovirals for treatment-experienced HIV... 
TRANSCRIPTASE INHIBITOR ETRAVIRINE | THERAPY | GENOTYPE | WARFARIN | QUANTIFICATION | TMC125 | PHARMACOLOGY & PHARMACY | PHARMACODYNAMICS | MODEL | INDIVIDUALIZATION | DESIGNS | HIV Infections - blood | HIV-1 - metabolism | Anti-Retroviral Agents - pharmacokinetics | HIV-1 - drug effects | HIV Infections - genetics | Humans | Cytochrome P-450 CYP2C19 - genetics | Male | Reverse Transcriptase Inhibitors - administration & dosage | Cytochrome P-450 CYP2C9 - genetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Anti-Retroviral Agents - administration & dosage | Drug Interactions - physiology | Pyridazines - administration & dosage | Adult | Cytochrome P-450 CYP2C19 - metabolism | Female | HIV Infections - drug therapy | Polymorphism, Genetic - genetics | Pyridazines - pharmacokinetics | Clinical Trials as Topic - methods | Drug Therapy, Combination | Cytochrome P-450 CYP2C9 - metabolism
Journal Article
Details down arrow
6. Full Text Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine
by Crauwels, Herta M and van Heeswijk, Rolf P.G and Buelens, Annemie and Stevens, Marita and Boven, Katia and Hoetelmans, Richard M.W
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2013, Volume 53, Issue 8, pp. 834 - 840
The objective of the study was to determine the impact of food and different meal types on the pharmacokinetics of rilpivirine, a nonnucleoside reverse... 
pharmacokinetics | nonnucleoside reverse transcriptase inhibitor | TMC278 | food effect | rilpivirine | Nonnucleoside reverse transcriptase inhibitor | Food effect | Pharmacokinetics | Rilpivirine | HIV-1 | PHASE-3 | HUMAN-IMMUNODEFICIENCY-VIRUS | TRIAL | RESISTANT | REVERSE-TRANSCRIPTASE INHIBITORS | ORAL BIOAVAILABILITY | EFAVIRENZ | PHARMACOLOGY & PHARMACY | ETRAVIRINE | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Biological Availability | Male | Reverse Transcriptase Inhibitors - administration & dosage | Nitriles - pharmacokinetics | Nitriles - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Reverse Transcriptase Inhibitors - pharmacokinetics | Proteins - administration & dosage | Dietary Fats - administration & dosage | Adult | Female | Dietary Sucrose | Fasting - metabolism | Meals | Breakfast | Administration, Oral | Pyrimidines - administration & dosage | Food-Drug Interactions | Food, Formulated | Cross-Over Studies | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Nitriles - adverse effects | Dosage and administration | Research | Drug interactions | Proteins | Confidence intervals | Bioavailability | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
by Spreen, William and Williams, Peter and Margolis, David and Ford, Susan L and Crauwels, Herta and Lou, Yu and Gould, Elizabeth and Stevens, Marita and Piscitelli, Stephen
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 12/2014, Volume 67, Issue 5, pp. 487 - 492
OBJECTIVE:Pharmacokinetics, safety, and tolerability of GSK1265744 (744) and rilpivirine (RPV) (TMC278) were assessed after repeat dosing of long-acting (LA)... 
Injections | GSK1265744 | Long-acting | Rilpivirine | TMC278 | Nanosuspension | Pharmacokinetics | injections | INFECTIOUS DISEASES | nanosuspension | pharmacokinetics | IMMUNOLOGY | long-acting | rilpivirine | Pyridones - pharmacokinetics | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Injections, Intramuscular | Nitriles - pharmacokinetics | Delayed-Action Preparations - administration & dosage | Nitriles - administration & dosage | Young Adult | Pyridones - administration & dosage | Drug Therapy, Combination - adverse effects | Drug Therapy, Combination - methods | Delayed-Action Preparations - adverse effects | Injections, Subcutaneous | Adolescent | Delayed-Action Preparations - pharmacokinetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Adult | Female | Nitriles - adverse effects | Pyridones - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A single‐dose, open‐label, parallel, randomized, dose‐proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia
by Cleton, Adriaan and Rossenu, Stefaan and Crauwels, Herta and Berwaerts, Joris and Hough, David and Gopal, Srihari and Eerdekens, Marielle and Vandebosch, An and Remmerie, Bart and De Meulder, Marc and Fernández, Clara M. Rosso
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2014, Volume 54, Issue 9, pp. 1048 - 1057
Paliperidone palmitate (PP) is a long‐acting injectable (LAI) antipsychotic, developed for monthly intramuscular (i.m.) administration into deltoid/gluteal... 
dose‐proportionality | long‐acting injectable | schizophrenia | paliperidone palmitate | dose-proportionality | long-acting injectable | 6-WEEK | EFFICACY | EXTENDED-RELEASE TABLETS | SAFETY | PREVENTION | RISPERIDONE | ANTIPSYCHOTICS | DRUGS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | SCALE | Schizophrenia - metabolism | Antipsychotic Agents - blood | Pyrimidines - blood | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Male | Psychiatric Status Rating Scales | Shoulder | Isoxazoles - blood | Adult | Female | Buttocks | Isoxazoles - pharmacokinetics | Pyrimidines - administration & dosage | Paliperidone Palmitate | Antipsychotic Agents - pharmacokinetics | Injections, Intramuscular | Isoxazoles - administration & dosage | Antipsychotic Agents - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Muscle, Skeletal | Schizophrenia - drug therapy | Isoxazoles - adverse effects | Dose-response relationship (Biochemistry) | Schizophrenia | Usage | Care and treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
by Cohen, Calvin J and Molina, Jean-Michel and Cassetti, Isabel and Chetchotisakd, Ploenchan and Lazzarin, Adriano and Orkin, Chloe and Rhame, Frank and Stellbrink, Hans-Jürgen and Li, Taisheng and Crauwels, Herta and Rimsky, Laurence and Vanveggel, Simon and Williams, Peter and Boven, Katia and THRIVE Study Grp and ECHO, THRIVE study groups
AIDS, ISSN 0269-9370, 03/2013, Volume 27, Issue 6, pp. 939 - 950
Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz... 
HIV-1 | Treatment naive | Rilpivirine | Efavirenz | INFECTIOUS DISEASES | ECHO | EMTRICITABINE | PHASE-3 | IMMUNOLOGY | THRIVE | rilpivirine | NUCLEOSIDE | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | IMMUNODEFICIENCY-VIRUS TYPE-1 | RESISTANCE | efavirenz | TENOFOVIR | treatment naive | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Young Adult | HIV-1 - isolation & purification | Adult | Female | Antiretroviral Therapy, Highly Active - methods | Benzoxazines - administration & dosage | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | HIV Infections - virology | Benzoxazines - adverse effects | Treatment Outcome | Drug-Related Side Effects and Adverse Reactions - epidemiology | Adolescent | Pyrimidines - adverse effects | HIV Infections - drug therapy | Aged | Nitriles - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials
by Cohen, Calvin J and Molina, Jean-Michel and Cahn, Pedro and Clotet, Bonaventura and Fourie, Jan and Grinsztejn, Beatriz and Wu, Hao and Johnson, Margaret A and Saag, Michael and Supparatpinyo, Khuanchai and Crauwels, Herta and Lefebvre, Eric and Rimsky, Laurence T and Vanveggel, Simon and Williams, Peter and Boven, Katia and ECHO Study Grp and THRIVE Study Grp and ECHO Study Group and THRIVE Study Group
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2012, Volume 60, Issue 1, pp. 33 - 42
BACKGROUND:Pooled analysis of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. METHODS:Treatment-naive... 
HIV-1 | Rilpivirine or RPV | Treatment-naive | Efavirenz or EFV | treatment-naive | INFECTIOUS DISEASES | REVERSE-TRANSCRIPTASE | EMTRICITABINE | IMMUNOLOGY | HIV-INFECTED ADULTS | COMBINATION | rilpivirine or RPV | efavirenz or EFV | VIROLOGICAL FAILURE | ACTIVE ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | DAILY LAMIVUDINE | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Rilpivirine | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Male | Viral Load | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Young Adult | HIV-1 - isolation & purification | Adult | Female | Antiretroviral Therapy, Highly Active - methods | Benzoxazines - administration & dosage | Double-Blind Method | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | HIV Infections - virology | Benzoxazines - adverse effects | Treatment Outcome | Adolescent | Pyrimidines - adverse effects | HIV Infections - drug therapy | Aged | Nitriles - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Transcription Profiles of Aortic Smooth Muscle Cells from Atherosclerosis-Prone and -Resistant Regions in Young Apolipoprotein E-Deficient Mice before Plaque Development
by Van Assche, Tim and Hendrickx, Jan and Crauwels, Herta M and Guns, Pieter-Jan and Martinet, Wim and Fransen, Paul and Raes, Martine and Bult, Hidde
Journal of Vascular Research, ISSN 1018-1172, 12/2010, Volume 48, Issue 1, pp. 31 - 42
Background/Aims: Site-specific atherosclerosis is generally attributed to differential gene expression in endothelial cells. We investigated whether the... 
Research Paper | Apolipoprotein E-deficient mice | Microarray | Smooth muscle cells | Atherosclerosis | PHYSIOLOGY | FLUID-FLOW | AMYLOID PRECURSOR PROTEIN | HOMEOBOX GENES | DISTURBED FLOW | SHEAR-STRESS | ENDOTHELIAL-CELLS | GENE-EXPRESSION | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | OSTEOPONTIN TRANSGENIC MICE | MECHANICAL STRETCH | Atherosclerosis - pathology | Age Factors | Oligonucleotide Array Sequence Analysis | Atherosclerosis - physiopathology | Atherosclerosis - genetics | Mice, Inbred C57BL | Male | Gene Expression Profiling | Muscle, Smooth, Vascular - cytology | Reverse Transcriptase Polymerase Chain Reaction | Aorta - pathology | Transcription, Genetic - physiology | Animals | Hypercholesterolemia - pathology | Mice, Mutant Strains | Apolipoproteins E - genetics | Female | Hypercholesterolemia - physiopathology | Mice | Aorta - physiopathology | Hypercholesterolemia - genetics | Muscle, Smooth, Vascular - physiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Drug interactions with new and investigational antiretrovirals
by Crauwels, Herta M and Kakuda, Thomas N
Clinical Pharmacokinetics, ISSN 0312-5963, 2010, Volume 49, Issue 1, pp. 67 - 68
PHARMACOLOGY & PHARMACY | Anti-HIV Agents - pharmacology | Pyrimidines - administration & dosage | Rilpivirine | Humans | Nitriles - pharmacokinetics | Anti-HIV Agents - administration & dosage | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Drug Interactions | Anti-HIV Agents - pharmacokinetics | Pyridazines - administration & dosage | Pyrimidines - pharmacokinetics | Pyridazines - pharmacokinetics
Journal Article
Details down arrow
13. Full Text Formulation and pharmacology of long-acting rilpivirine
by Williams, Peter E and Crauwels, Herta M and Basstanie, Esther D
Current Opinion in HIV and AIDS, ISSN 1746-630X, 07/2015, Volume 10, Issue 4, pp. 233 - 238
PURPOSE OF REVIEWRilpivirine (RPV), a nonnucleoside reverse transcriptase inhibitor, is a potent antiretroviral (ARV) effective for HIV treatment at 25 mg... 
Cabotegravir | Nanosuspension | Rilpivirine | Long-acting injectable antiretroviral | long-acting injectable antiretroviral | INFECTIOUS DISEASES | nanosuspension | SAFETY | PREVENTION | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | rilpivirine | REVERSE-TRANSCRIPTASE INHIBITOR | TRIAL | PROPHYLAXIS | PHARMACOKINETICS | TOLERABILITY | TMC278 | cabotegravir | HIV-1 INFECTION | Anti-HIV Agents - pharmacology | HIV-1 | HIV Infections - virology | Humans | Reverse Transcriptase Inhibitors - pharmacology | Rilpivirine - chemistry | Reverse Transcriptase Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - chemistry | Anti-HIV Agents - administration & dosage | Anti-HIV Agents - chemistry | Rilpivirine - pharmacology | HIV Infections - drug therapy | Rilpivirine - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women
by Moti Ramgopal and Olayemi Osiyemi and Carmen Zorrilla and Herta M Crauwels and Robert Ryan and Kimberley Brown and Vera Hillewaert and Bryan Baugh
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 11/2016, Volume 73, Issue 3, p. 268
  Background: Treatment of HIV-1-infected women during pregnancy protects maternal health and reduces the risk of perinatal transmission of HIV-1. However,... 
Pregnancy | Antiretroviral drugs | Disease transmission | Maternal & child health | Human immunodeficiency virus--HIV | Reaction kinetics | Pharmacology
Journal Article
Details down arrow
15. Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women
by Ramgopal, Moti and Osiyemi, Olayemi and Zorrilla, Carmen and Crauwels, Herta M and Ryan, Robert and Brown, Kimberley and Hillewaert, Vera and Baugh, Bryan
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 11/2016, Volume 73, Issue 3, pp. 268 - 268
Background: Treatment of HIV-1-infected women during pregnancy protects maternal health and reduces the risk of perinatal transmission of HIV-1. However,... 
Journal Article
Details down arrow
16. Full Text Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study
by Osiyemi, Olayemi and Yasin, Salih and Zorrilla, Carmen and Bicer, Ceyhun and Hillewaert, Vera and Brown, Kimberley and Crauwels, Herta M
Infectious Diseases and Therapy, ISSN 2193-8229, 3/2018, Volume 7, Issue 1, pp. 147 - 159
Physiologic changes during pregnancy may impact the pharmacokinetics of drugs. In addition, efficacy and safety/tolerability concerns have been identified for... 
Pregnancy | Medicine & Public Health | HIV | Rilpivirine | Internal Medicine | Infectious Diseases | Pharmacokinetics | Antiretroviral drugs | Human immunodeficiency virus--HIV | Patient safety | Clinical trials | Pharmacology | Clinical outcomes | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17.